Skip to Content

Qiagen NV QGEN

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Qiagen's COVID-19 Momentum Continues in Fourth Quarter; Maintaining Fair Value Estimate

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Qiagen turned in fourth-quarter results that continued well above its historical growth trajectory based on increased demand for its products to combat the pandemic. The company also maintained its 2021 guidance that was originally given at its investor day in December. That strong outlook caused us to raise our fair value estimate in late 2020, and this outlook confirmation does not materially change our view of the firm. Also, similar to many companies in life sciences that have seen a boost from COVID-19-related demand, we continue to view Qiagen's stock as rich.

Read Full Analysis

Company Profile

Business Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (47%), followed by EMEA (32%) and Asia-Pacific (21%).

Hulsterweg 82
Venlo, 5912 PL, Netherlands
T +31 773556600
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 5,300